

# nNOS at a glance: implications for brain and brawn

Imran N. Mungrue and David S. Bredt\*

Department of Physiology, University of California at San Francisco School of Medicine, 513 Parnassus Avenue, San Francisco, California, CA 94143-0444, USA

\*Author for correspondence (e-mail: bredt@itsa.ucsf.edu)

Journal of Cell Science 117, 2627-2629  
Published by The Company of Biologists 2004  
doi:10.1242/jcs.01187


Nitric oxide (NO), formed enzymatically from L-arginine, functions as an endogenous signaling molecule in numerous organs and tissues throughout the animal and plant kingdoms. The first NO synthase (NOS) was isolated from

mammalian brain and named neuronal NOS (nNOS, aka: NOS1) owing to its localization in neurons (Bredt et al., 1990; Bredt and Snyder, 1990). NO plays several important roles in the brain, including in regulation of synaptic signalling and plasticity. Additionally, high levels of nNOS protein are present in skeletal muscle (Brennan et al., 1995), where NO controls muscle contractility (Kobzik et al., 1994) and local blood flow (Thomas et al., 1998). nNOS activity is primarily regulated by increases in intracellular Ca<sup>2+</sup>, which activate nNOS through calmodulin binding (Bredt and Snyder, 1990). NOS enzymes are homodimeric proteins. Recent studies show that NO actions in brain and muscle also rely crucially upon the association of nNOS with specific protein complexes in neurons and muscle cells, respectively. These

physical interactions with nNOS allow for integration of NO signalling into distinct transduction cascades in specific cell types.

## Neuronal nNOS

In the brain, the 160kDa nNOS $\alpha$  is the predominant splice variant, and contains an N-terminal PSD/Discs-large/ZO-1 homologous (PDZ)-binding domain, which anchors this complex to the postsynaptic density in the vicinity of the N-methyl-D-aspartate type-glutamate receptor (NMDAR). The PDZ domain of nNOS binds to a similar PDZ domain from the postsynaptic density protein, PSD-95, which in turn binds to the cytosolic tail of the NMDAR (Christopherson et al., 1999). These molecular interactions explain how Ca<sup>2+</sup> influx through NMDA receptors is



(See poster insert)

efficiently coupled to NO synthesis and activity (Sattler et al., 1999). Following its synthesis at postsynaptic sites, NO may diffuse back to the presynaptic terminal (Haley et al., 1992; Shibuki and Okada, 1991) and increase cGMP levels through activation of soluble guanylate cyclase (GC) (Boulton et al., 1994, 1995).

This membrane-localized nNOS complex is further linked to cytoplasmic signal transduction pathways via the physical interaction of nNOS with DexRas 1 and the adapter protein CAPON (Fang et al., 2000), which might activate a downstream MAP kinase cascade and modulate nuclear transcription. Functionally, nNOS might also represent a central component that regulates synaptic transmission and intercellular signaling, through negative regulation of the NMDAR by S-nitrosylation (Kim et al., 1999) and NO-dependent activation of DexRas (Fang et al., 2000). Additionally, the half-life of neuronal nNOSa protein is regulated by the Ca<sup>2+</sup> sensitive protease calpain (Hajimohammadreza et al., 1997).

Whereas the small quantities of NO formed during synaptic transmission modulate neuronal signaling, excess NO mediates neurotoxicity in pathological situations, such as an ischemic stroke (Huang et al., 1994). This NO toxicity is accentuated in the presence of oxidative radicals such as O<sub>2</sub><sup>-</sup>, which can also be generated by nNOS (Pou et al., 1992). Interestingly, nNOS-expressing neurons are spared from injury associated with elevated NO, which might partly be because of the physical association of nNOS with phosphofructokinase-M (PFK), the rate-limiting enzyme in glycolysis (Firestein and Bredt, 1999). Consequently, while therapeutic modulation of nNOS represents a potentially important approach in the setting of several clinically important neurological diseases, the balance between positive and negative effects of nNOS derived NO in the brain are complex and must be carefully weighed.

### Skeletal muscle nNOS $\mu$

Skeletal muscle contains an alternatively spliced nNOS $\mu$  isoform that, when translated, results in the addition of a 34

amino acid segment within the reductase domain (Silvagno et al., 1996). NO is formed in contracting muscle, diffuses out of the muscle fibers and dilates adjacent blood vessels (Persson et al., 1990), by activating soluble guanylate cyclase (sGC) in arterial smooth muscle. This pathway helps to link skeletal muscle activity to increased local blood flow. Skeletal muscle nNOS $\mu$  is bound to the dystrophin associated protein complex through interaction of the nNOS $\mu$  PDZ domain and  $\alpha$ -syntrophin (Brenman et al., 1996). Importantly, mutations of dystrophin (Brenman et al., 1995) or sarcoglycan (Crosbie et al., 2002) that underlie human muscular dystrophy cause a selective loss of nNOS $\mu$  from muscle membranes and thereby impair local blood flow (Grange et al., 2001). Furthermore, transgenic restoration of nNOS $\mu$  alleviates pathology in animal models of muscular dystrophy (Wehling et al., 2001), suggesting that NO augmentation represents a strategy to treat certain muscular dystrophies. Similar to nNOS $\alpha$  in brain, nNOS $\mu$  protein turnover in skeletal muscle is also regulated by Ca<sup>2+</sup>-dependent calpain degradation (Laine and de Montellano, 1998).

### Cardiac Muscle nNOS $\mu$

An nNOS protein with the same electrophoretic mobility as nNOS $\mu$  localizes to the sarcoplasmic reticulum of cardiac muscle (Xu et al., 1999), and might be associated with the ryanodine receptor (Sears et al., 2003). The role of nNOS in the cardiac myocyte is complex and might regulate Ca<sup>2+</sup> dynamics through activation of the ryanodine receptor (RyR), inhibition of sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA) or the L-type Ca<sup>2+</sup> channel, or through increasing phospholamban (PLB) protein levels (Sears et al., 2003). Interestingly, cardiac defects are common in muscular dystrophy (Emery, 2002) and are correlated with the down-regulation of cardiac nNOS expression (Bia et al., 1999). Future studies examining the roles of nNOS in the heart have important clinical implications. However, owing to the complex and crucial roles for nNOS and NO in cardiomyocyte signaling, and the potential for superoxide generation from excessive nNOS activity, therapeutic modulations

must be performed with care to prevent adverse cardiac effects.

### Smooth muscle nNOS

While endothelial NOS (eNOS)-derived NO is important in the regulation of arterial physiology and blood pressure, the identification of nNOS and nNOS $\mu$  in arterial smooth muscle (Boulanger et al., 1998; Schwarz et al., 1999) suggests that nNOS also participates in the regulation of vascular perfusion. Furthermore, neuron- (Hara et al., 1996) or skeletal-muscle-derived (Lau et al., 2000) NO generated from nNOS might also relax blood vessels, indicating that eNOS is not the sole modulator of NO-dependent arterial tone. Recent evidence also suggests that nNOS in smooth muscle is localized to caveoli in association with caveolin 1 and the plasma membrane Ca<sup>2+</sup> efflux pump 4 (PMCA 4) (Schuh et al., 2001). By extruding Ca<sup>2+</sup>, PMCA 4 might serve a role in the negative regulation of nNOS in the caveoli micro-domain and limit NO generation (Schuh et al., 2001).

I.N.M. has a Post Doctoral Fellowship supported from the Canadian Institutes for Health Research/Heart and Stroke Foundation of Canada/Canadian Stroke Network/AstraZeneca Canada. D.S.B. is supported by grants from the National Institutes of Health and the American Heart Association.

### References

- Bia, B. L., Cassidy, P. J., Young, M. E., Rafael, J. A., Leighton, B., Davies, K. E., Radda, G. K. and Clarke, K.** (1999). Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. *J. Mol. Cell Cardiol.* **31**, 1857-1862.
- Boulanger, C. M., Heymes, C., Benessiano, J., Geske, R. S., Levy, B. I. and Vanhoutte, P. M.** (1998). Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. *Circ. Res.* **83**, 1271-1278.
- Boulton, C. L., Irving, A. J., Southam, E., Potier, B., Garthwaite, J. and Collingridge, G. L.** (1994). The nitric oxide-cyclic GMP pathway and synaptic depression in rat hippocampal slices. *Eur. J. Neurosci.* **6**, 1528-1535.
- Boulton, C. L., Southam, E. and Garthwaite, J.** (1995). Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. *Neuroscience* **69**, 699-703.
- Bredt, D. S. and Snyder, S. H.** (1990). Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. *Proc. Natl. Acad. Sci. USA* **87**, 682-685.
- Bredt, D. S., Hwang, P. M. and Snyder, S. H.** (1990). Localization of nitric oxide synthase

indicating a neural role for nitric oxide. *Nature* **347**, 768-770.

**Brenman, J. E., Chao, D. S., Xia, H., Aldape, K. and Bredt, D. S.** (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell* **82**, 743-752.

**Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., et al.** (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. *Cell* **84**, 757-767.

**Christopherson, K. S., Hillier, B. J., Lim, W. A. and Bredt, D. S.** (1999). PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. *J. Biol. Chem.* **274**, 27467-27473.

**Crosbie, R. H., Barresi, R. and Campbell, K. P.** (2002). Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. *FASEB J.* **16**, 1786-1791.

**Emery, A. E.** (2002). The muscular dystrophies. *Lancet* **359**, 687-695.

**Fang, M., Jaffrey, S. R., Sawa, A., Ye, K., Luo, X. and Snyder, S. H.** (2000). Dexas1: a G protein specifically coupled to neuronal nitric oxide synthase via CAPON. *Neuron* **28**, 183-193.

**Firestein, B. L. and Bredt, D. S.** (1999). Interaction of neuronal nitric-oxide synthase and phosphofruktokinase-M. *J. Biol. Chem.* **274**, 10545-10550.

**Grange, R. W., Isotani, E., Lau, K. S., Kamm, K. E., Huang, P. L. and Stull, J. T.** (2001). Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles. *Physiol. Genomics* **5**, 35-44.

**Hajimohammadreza, L., Raser, K. J., Nath, R., Nadimpalli, R., Scott, M. and Wang, K. K.** (1997). Neuronal nitric oxide synthase and calmodulin-dependent protein kinase IIalpha undergo neurotoxin-induced proteolysis. *J. Neurochem.* **69**, 1006-1013.

**Haley, J. E., Wilcox, G. L. and Chapman, P. F.** (1992). The role of nitric oxide in hippocampal long-term potentiation. *Neuron* **8**, 211-216.

**Hara, H., Huang, P. L., Panahian, N., Fishman, M. C. and Moskowitz, M. A.** (1996). Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. *J. Cereb. Blood Flow Metab.* **16**, 605-611.

**Huang, Z., Huang, P. L., Panahian, N., Dalkara, T., Fishman, M. C. and Moskowitz, M. A.** (1994). Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. *Science* **265**, 1883-1885.

**Kim, W. K., Choi, Y. B., Rayudu, P. V., Das, P., Asaad, W., Arnelle, D. R., Stamler, J. S. and Lipton, S. A.** (1999). Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO. *Neuron* **24**, 461-469.

**Kobzik, L., Reid, M. B., Bredt, D. S. and Stamler, J. S.** (1994). Nitric oxide in skeletal muscle. *Nature* **372**, 546-548.

**Laine, W. K., Choi, Y. B., Rayudu, P. V., Das, P., Asaad, W., Arnelle, D. R., Stamler, J. S. and Lipton, S. A.** (1999). Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO. *Neuron* **24**, 461-469.

**Lau, K. S., Grange, R. W., Isotani, E., Sareljus, I. H., Kamm, K. E., Huang, P. L. and Stull, J. T.** (2000). nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. *Physiol. Genomics* **2**, 21-27.

**Persson, M. G., Gustafsson, L. E., Wiklund, N. P., Hedqvist, P. and Moncada, S.** (1990). Endogenous nitric oxide as a modulator of rabbit skeletal muscle microcirculation in vivo. *Br. J. Pharmacol.* **100**, 463-466.

**Pou, S., Pou, W. S., Bredt, D. S., Snyder, S. H. and Rosen, G. M.** (1992). Generation of superoxide by purified brain nitric oxide synthase. *J. Biol. Chem.* **267**, 24173-24176.

**Sattler, R., Xiong, Z., Lu, W. Y., Hafner, M., MacDonald, J. F. and Tymianski, M.** (1999). Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. *Science* **284**, 1845-1848.

**Schuh, K., Uldrijan, S., Telkamp, M., Rothlein, N. and Neyses, L.** (2001). The plasmamembrane calmodulin-dependent calcium pump: a major regulator of nitric oxide synthase I. *J. Cell Biol.* **155**, 201-205.

**Schwarz, P. M., Kleinert, H. and Forstermann, U.** (1999). Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. *Arterioscler. Thromb. Vasc. Biol.* **19**, 2584-2590.

**Sears, C. E., Bryant, S. M., Ashley, E. A., Lygate, C. A., Rakovic, S., Wallis, H. L., Neubauer, S., Terrar, D. A. and Casadei, B.** (2003). Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. *Circ. Res.* **92**, E52-E59.

**Shibuki, K. and Okada, D.** (1991). Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. *Nature* **349**, 326-328.

**Silvagno, F., Xia, H. and Bredt, D. S.** (1996). Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle. *J. Biol. Chem.* **271**, 11204-11208.

**Thomas, G. D., Sander, M., Lau, K. S., Huang, P. L., Stull, J. T. and Victor, R. G.** (1998). Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. *Proc. Natl. Acad. Sci. USA* **95**, 15090-15095.

**Wehling, M., Spencer, M. J. and Tidball, J. G.** (2001). A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. *J. Cell Biol.* **155**, 123-131.

**Xu, K. Y., Huso, D. L., Dawson, T. M., Bredt, D. S. and Becker, L. C.** (1999). Nitric oxide synthase in cardiac sarcoplasmic reticulum. *Proc. Natl. Acad. Sci. USA* **96**, 657-662.

**Cell Science at a Glance on the Web**  
Electronic copies of the poster insert are available in the online version of this article at [jcs.biologists.org](http://jcs.biologists.org). The JPEG images can be downloaded for printing or used as slides.

## Commentaries

JCS Commentaries highlight and critically discuss recent exciting work that will interest those working in cell biology, molecular biology, genetics and related disciplines. These short reviews are commissioned from leading figures in the field and are subject to rigorous peer-review and in-house editorial appraisal. Each issue of the journal contains at least two Commentaries. JCS thus provides readers with more than 50 Commentaries over the year, which cover the complete spectrum of cell science.

Although we discourage submission of unsolicited Commentaries to the journal, ideas for future articles – in the form of a short proposal and some key references – are welcome and should be sent to the Executive Editor at the address below.

Journal of Cell Science, Bidder Building, 140 Cowley Rd, Cambridge, UK CB4 0DL  
E-mail: [jcs@biologists.com](mailto:jcs@biologists.com) <http://jcs.biologists.org>